4D Molecular Therapeutics Inc. (FDMT) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, 4D Molecular Therapeutics Inc. (NASDAQ: FDMT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.37 (-4.45% 1D, market cap $657.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FDMT ranks #391 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FDMT carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, SLDB (Solid Biosciences Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $664.8M) and SLBT (SL Science Holding Limited) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $672.9M). Among the 5-stock peer group, FDMT leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
Per FDMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650648), 4D Molecular Therapeutics Inc. generated $85.2M in revenue (+230194.6% YoY), -$140.1M in net income, and -$109.6M in free cash flow against $566.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 5.17 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 44% of 52W Range • RSI-14 at 45 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While FDMT currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.58) and Max Pain ($11.94) forces dealer call-delta covering toward $17.78.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
4D Molecular Therapeutics Inc. (FDMT) dropped -4.45% to $11.37, trading at 44% of its 52-week range ($6.96 – $16.93). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
Seeking Alpha report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $36 price target.
Recently published Cystic Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, cystic fibrosis emerging drugs, market share of individual therapies, and current and forec
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on FDMT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for FDMT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, 4D Molecular Therapeutics Inc. (FDMT) ranks #391 by composite RQD confidence (44/100, grade D) and #403 by equity capitalization ($657.4M). Within this direct 5-issuer industry benchmark cohort, FDMT leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. SLBT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with FDMT at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FDMT
ACTIVE
4D Molecular Therapeutics Inc. | D | 44/100 | — | — | -28.3% | -4.45% | $657.4M | Benchmark Subject |
| SLDB Solid Biosciences Inc. | E | 26/100 | — | — | -35.0% | -3.23% | $664.8M | /sldb-vs-fdmt → |
| SLBT SL Science Holding Limited | D | 45/100 | — | — | — | +5.83% | $672.9M | /slbt-vs-fdmt → |
| CADL Candel Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -2.52% | $637.4M | /cadl-vs-fdmt → |
| AURA Aura Biosciences Inc. | E | 29/100 | — | — | -35.0% | -1.79% | $636.7M | /aura-vs-fdmt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), 4D Molecular Therapeutics Inc. (FDMT) reported GAAP revenue of $85.2M (+230194.6% vs. FY2024 revenue of $37.0K , and +311.2% cumulative change since FY2023) , GAAP net income of -$140.1M, operating cash flow of -$109.1M, and free cash flow of -$109.6M (+20.8% YoY). On the balance sheet, FDMT closed FY2025 with $566.7M in total assets against $0 in total debt (Altman Z-Score: 5.17, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $85.2M | -$140.1M | -$109.1M | -$109.6M | $566.7M | $0 |
| FY2024 (FY) | 2024-12-31 | $37.0K | -$160.9M | -$134.6M | -$138.4M | $560.4M | — |
| FY2023 (FY) | 2023-12-31 | $20.7M | -$100.8M | -$75.8M | -$75.8M | — | — |
As of 2026-11-03, 4D Molecular Therapeutics Inc. (NASDAQ: FDMT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.37 (-4.45% 1D, market cap $657.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FDMT ranks #391 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FDMT carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, SLDB (Solid Biosciences Inc.) holds a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $664.8M) and SLBT (SL Science Holding Limited) posts a D grade (45/100 RQD, P/E N/A, ROIC —, cap $672.9M). Among the 5-stock peer group, FDMT leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
Per FDMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650648), 4D Molecular Therapeutics Inc. generated $85.2M in revenue (+230194.6% YoY), -$140.1M in net income, and -$109.6M in free cash flow against $566.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
FDMT last traded at $11.37 (-4.45% on volume of 734,806 shares), positioning the stock -16.27% below its 50-day simple moving average ($13.58) and +4.12% above its 200-day simple moving average ($10.92). Across its 52-week range of $6.96 to $16.93, FDMT sits at the 44.2% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.95 to $12.79).
FDMT scores 45 out of 100, earning a letter grade of D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
For a prospective investor, the picture is a company with a reasonable balance sheet funding a deeply loss-making operation. Upside drivers are the two pivotal readouts for 4D-150 that the news wire says are expected in 2027. The weak insider and cash-flow pillars point to distribution risk, so the score argues for caution rather than accumulation on current evidence.
. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Revenue in FY 2025 was $85.
Per the market data, gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -28.3%. Per the RQD rating, the Altman Z-Score is 5.17 and the Piotroski F-Score is 5/9. Cash declined from $149.3M in FY 2024 to $60.2M in FY 2025 against zero reported debt in FY 2025, which indicates the balance sheet is funding losses from reserves.
Supply_chain is NONE and butterfly_links is empty. Upstream and downstream dependencies are — Sector correlation is not quantified in the source data. A prospective investor should watch the 2027 pivotal readouts for 4D-150, since the source data indicates these are the event on which the company's trajectory depends, but the graph provides no mapped ripple effects.
Real-time company headlines, analyst actions, and sector developments for 4D Molecular Therapeutics Inc. (FDMT) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering 4D Molecular Therapeutics Inc. (FDMT) market action, institutional positioning, and fundamental catalysts.
Don't sleep on FDMT's setup in Health Care. A balance sheet with a 5.17 Altman Z-Score and zero reported debt gives the company room to reach the 2027 pivotal 4D-150 readouts.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (44/100) backs up the fundamental quality.
@RiskArb_Desk Shorting a 8/20 institutional whale-flow stock at $11.90 is dangerous when funds are rotating into Health Care.
I respect the product at 4D Molecular Therapeutics Inc., but the stock at $11.90 is a different story. A -60% operating margin, -28.3% ROIC, and insider selling in the news wire point to continued cash burn and distribution risk.. FCF yield is -15.53% and RQD sits at 44/100 (D) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).